PMID- 35795855
OWN - NLM
STAT- MEDLINE
DCOM- 20220708
LR  - 20231101
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk 
      in Anti-Breast Cancer Therapy.
PG  - 4831833
LID - 10.1155/2022/4831833 [doi]
LID - 4831833
AB  - Cancer is one of the leading causes of death worldwide. Breast cancer is the 
      second leading cause of death in women, with triple-negative breast cancer being 
      the most lethal and aggressive form. Conventional therapies, such as radiation, 
      surgery, hormonal, immune, gene, and chemotherapy, are widely used, but their 
      therapeutic efficacy is limited due to adverse side effects, toxicities, 
      resistance, recurrence, and therapeutic failure. Many molecules have been 
      identified and investigated as potential therapeutic agents for breast cancer, 
      with a focus on various signaling pathways. Flavonoids are a versatile class of 
      phytochemicals that have been used in cancer treatment to overcome issues with 
      traditional therapies. Cell proliferation, growth, apoptosis, autophagy, and 
      survival are all controlled by mammalian target of rapamycin (mTOR) signaling. 
      Flavonoids target mTOR signaling in breast cancer, and when this signaling 
      pathway is regulated or deregulated, various signaling pathways provide potential 
      therapeutic means. The role of various flavonoids as phytochemicals in targeting 
      mTOR signaling pathways in breast cancer is highlighted in this review.
CI  - Copyright (c) 2022 Yaseen Hussain et al.
FAU - Hussain, Yaseen
AU  - Hussain Y
AUID- ORCID: 0000-0003-1054-6720
AD  - College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
AD  - Department of Pharmacy, Bashir Institute of Health Sciences, Islamabad, Pakistan.
FAU - Khan, Haroon
AU  - Khan H
AUID- ORCID: 0000-0002-1736-4404
AD  - Department of Pharmacy, Faculty of Chemical and Life Sciences, Abdul Wali Khan 
      University, Mardan 23200, Pakistan.
FAU - Alam, Waqas
AU  - Alam W
AUID- ORCID: 0000-0001-8329-9180
AD  - Department of Pharmacy, Faculty of Chemical and Life Sciences, Abdul Wali Khan 
      University, Mardan 23200, Pakistan.
FAU - Aschner, Michael
AU  - Aschner M
AUID- ORCID: 0000-0002-2619-1656
AD  - Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, 
      NY 10461, USA.
FAU - Abdullah
AU  - Abdullah
AD  - Department of Pharmacy, University of Malakand, Chakdara, Dir Lower, Pakistan.
FAU - Alsharif, Khalaf F
AU  - Alsharif KF
AUID- ORCID: 0000-0002-8156-2069
AD  - Department of Clinical Laboratory, College of Applied Medical Science, Taif 
      University, P.O. Box 11099, Taif 21944, Saudi Arabia.
FAU - Saso, Luciano
AU  - Saso L
AUID- ORCID: 0000-0003-4530-8706
AD  - Department of Physiology and Pharmacology "Vittorio Erspamer" Sapienza 
      University, 00185 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220627
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Flavonoids)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Cell Proliferation
MH  - Female
MH  - *Flavonoids/pharmacology/therapeutic use
MH  - Humans
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - *Triple Negative Breast Neoplasms
PMC - PMC9252758
COIS- The authors declared that there is no conflict of interest.
EDAT- 2022/07/08 06:00
MHDA- 2022/07/09 06:00
PMCR- 2022/06/27
CRDT- 2022/07/07 02:38
PHST- 2022/01/24 00:00 [received]
PHST- 2022/06/04 00:00 [accepted]
PHST- 2022/07/07 02:38 [entrez]
PHST- 2022/07/08 06:00 [pubmed]
PHST- 2022/07/09 06:00 [medline]
PHST- 2022/06/27 00:00 [pmc-release]
AID - 10.1155/2022/4831833 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Jun 27;2022:4831833. doi: 10.1155/2022/4831833. 
      eCollection 2022.